Research & Development

Merrimack Pharmaceuticals, Inc. has announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific antibody targeting Read more
In the first study of its kind, researchers have demonstrated novel and previously unknown mechanisms of action Read more